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Published opinions concerning treatment of myocardial 
ischemia include 1) the concern that pursuit of medical 
therapy beyond elimination cf symptomatic episodes of 
ischemia may not be beneficial (2); 2) the acceptance that 
total ischemic activity should be treated, acknowledging 
that it has not been proved that such treatment will im- 
prove prognosis (3); and 3) the belief that ischemia, whether 
it manifests with angina or remains ilent, should be 
tected and treated to improve prognosis (4). Results of 
previous clinical trials suggest that revascularization of 
symptomatic patients in stable condition probably does not 
alter survival compared with routine medical management, 
except in patients with either left main coronary artery 
stenosis (5,6) or three-vessel obstruction and decreased 
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left ventricular function (7) 
vessel disease (6). 
in some patients with multiple- 
farction), the Asymptomatic Cardiac 
trocardiographic (ECG) monitoring or with a strategy to 
alleviate significant coronary obstruction by revas 
tion. The purpose of this report is to describe the 
these three treatment strategies on suppression f 
at the week 12 visit, the primary outcome ofthe AC 
ves. Details of the ACIP study des 
SC Pepine t al. (1). Briefly, the majot 
the ACIP study, a multicenter, inte~atio~al clinical trial 
iond Heart, Lung and Blood Institute are 
e safety and efficacy of three randomly 
uppress i chemia, nd 2) to assess the 
trial to evaluate the effects of anti- 
n mortality and morbidity, including 
ascettainment of the availability ofpatients, compliance with 
as and event rates at 1year. 
and women who had I) angigraphic 
evidence ofobstructive coronary artery disease amenable to
revascularization; 2) evidence of stress-related iscbemia 
during an ACIP protocol treadmill (8) or an ~teroative stress 
test if the patient could not exercise; and 3) at least one 
episode of asymptomatic is hemia (ST segment deviation 
21 mm from baseline rl min and separated from other 
episodes by at least 5 min) on a 48-h ambulatory electrocar- 
diogram (ECG) were ligible. The stress test and ambulatory 
ECG were performed after all anti-ischemic medication (but 
sublingual nitroglycerin) had been discontinued forat least 2 
to 3 days, except for postinfarction patients who could 
continue taking atenolol(50 mg once a day) or a slow-release 
or diltiazem (Cardizem 
During the 1st 4 weeks after randomization, unblinded 
medication (either atenolol plus nifedipine or diltiazem plus 
isosorbide dinitrate) was titrated in all treatment groups to 
relieve angina. The dose sequence ofeach regimen isshown 
in Table 1. 
At the end of 4 and 8 weeks, a48-h ambulatory ECG was 
obtained for patients a signed toreceive medical therapy. If 
the ambulatory ECG core laboratory detected ischemia, the 
clinical coordinating center motified the clinical unit 
blinded medication should be started or increased (1). 
ther patient nor clinical unit stti knew whether the medica- 
tion was active or placebo. Blinded medications were either 
active atenolol plus nifedipine or diltiazem plus isosorbide 
dinitrate on the basis of regimen assignment for patients 
assigned to ischemia-guided strategy or blinded placebos 
matching the active medication i  the assigned regimen for 
patients assigned to the angina-guided strategy. At all times 
clinical events, such 
peffo~ed by an ind 
sification Committee. 
ary outcome. The pri- 
was absence of iscbemic 
z I min) on the week 
12 ambulatory ECG. atients who died 
myocardial infarction a revascularizatio 
called for by study protocol before the we 
counted as having ischemia “present” on the week 12 
ambulatory ECG, rega s of ambulatory ECG findings. It
was determined that - patients in each treatment strat- 
egy would result in acceptable power for comparing the 
percent of patients free of ischemia mong the three treat- 
ment strategies (1). A likelihood ratio test using logistic 
regression (9) was to determine whether there 
gina at entry and treatment. 
ustment (IO) was used to maimtain an 
overall alpha-level of 0.10 -flhile performing three pairwise 
comparisons; that is, p < 0.033 was required to reject he 
null hypothesis in each pairwise test. Adjusted odds ratios 
and confidence intervals were calculated from the logistic 
En al! analyses, patients were 
data processed in the clini I coordinating center as of 
January 4, 1994 were includ 
Enrolll , 1991 toFebruary 1, 1993, 
618 patients were enrolled (Fig. 1) and assigned toone oft 
three treatment s rategies; 363 (59%) were also assigned 
randomly to receive either the atenolol plus nifedipinc or 
ent strategies are de 
(11%) patients did not have revasc~~arizatio~~ because either 
the patient or the patient’s physician refnsed after enroll- 
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N=Bl 
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N-49 
D/i 
N=39 
The Asymptomatic Cardiac Ischemia Pilot study design 
ber of patients assigned to each treatment 
plus nifedipine; CABG = coronary arte 
D/l = diltiazem plus isosorbide dinitrate; 
taneous transluminal coronary angioplasty. 
ment. Nine of the 189 pr~edures were r 12 
weeks. The median number of days from s 18 
hit an~io~~rn~ 36 (3541 of 
plasty had only one vessel 
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ur erects: one 
Average daily dose. The 
medication for patients t&in 
ment strategy and regimen in 
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r 
Figure 2. Medication at week 12 visit. Left 
show unblinded medication used in 
-guid 
strategies. show unblinded 
medicatinn 
tion (unblinded and blinded) (C, 
ischemia-guided strategy. 
A~gi~a”~~~~e~ Strategy ~eVasC~~a~~at!W~ Strdtegy 
N fm 
m nos) b-l = 112) 
No. NO. No. No. No. NO. 
of PEG m@aY of Rs W.@ay ofFis Zg,‘&~ cf’ Rs @day of as nag/da:, Gf Rts @day 
Total active flle~~cati~a 
36 61 4 56 86 133 6 112 41 64 2 15 
21 50 1 30 50 62 4 68 8 38 1 60 
9 153 73 B I 239 76 288 I 180 30 162 
13 28 5 112 41 83 0 0 9 56 
No ~e~~cati~~ 1 15 6 11 67 65 
No visit 5 3 4 2 2 2 
twitched ~e~i~e~s (%) 9 5 8 7 1 2 
AiN = ateaolol plus nife = ~~~t~~~e~ phs isosorbidc ~~a~t~t~ regimen; i!XlN = isosorbide dinitrate; Rs = patients. 
(Table 2). 
Amhu~atory ECG resays. Al qualifying visit, The ga- 
tients assigned to the revascularization strategy had some- 
what more ischemic episodes, and the total duration of 
ischemia per 48 h was longer than for patients a signed to 
either of the medical strategies (Table 3); these differences 
were not significantly different. As permitted by protocol, 
-20% of patients in all thre strategies were taking back- 
ground medication, (i.e., lo ose of atenolol r diltiazem). 
Primary outcome. At the week 12 visit, the of 
patients with no ischemic episodes (p~mary out as 
-39% in the augi~a-guided strategy, 41% in ischemia-guided 
strategy and 55% inthe revascularization strategy (T 
Fig. 3). The global test for any treatment differences (likeli- 
hood ratio test using logistic regression model adjusting for 
number of ischemic episodes per 48 h on the qualifying 
days before completing the week 12 visit; this patient was 
counted with ischemiaat I2weeks. Three additional patients 
also had myocardial infarction, and four patients had non- 
protocol revas~u~arizatioa af er $4 days and before co 
ing the week 12 visit; all were considered to
present (Table 3). 
Of the patients assigned tothe revascu~arjzation s rategy, 
bypass urgery, of whom 82 had wee 
and 58 (71%) were iscbemia free; 
gioplasty completed, of whom $6 bad week 
CGs, and 46 (53%) were ischemia free. 
Symptomatic and asymptomaticpatients. The percen 
patients with no ischemia on the week 12 ambulatory E 
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T 3. Ambulatory Electrocardiographic Results by Visit and Treatment S rategy -- --- -- 
Qualifying Visit Week 12 Visit 
Angina-Guided Ischemia-Guided Revascularization Angina-Guided Ischemia-Guided ~evascula~2at~o~ 
Strategy Strategy Strategy Q Strategy Strategy Strategy Q 
(n = 204) (n = 202) (n = 212) Value (i-l= 204) (n = 2021 (II = 212) Value 
_- ..-- -.-I_ 
No. of ischemic 
episodesl 
48 h: no. (%) of Qts 
0 
I 
2 
3 
4 
h5 
Event (ischemia) 
Not available 
No. (%I of pls with 
236 h of recording 
or event 
Distribution of ischemic 
episodes 
25th percentile 
50th percentile 
75th percentile 
TOM ischemic time on 
AECG (min) 
25th percentile 
50th percentile 
75th percentile 
Mean length of recording 
(h) 
Mean time from entry 
(days) 
Mean (*SD) heart rate 
(beatslmin) 
Entire recording 
Maximal 
At time of ischemic 
episode 
0 0 0 
4luw 3Y (IY) 38 (18) 
56 (271 47 (23) 38 (18) 
27 (I31 27 (13) 22 (IU) 
20 (IO) 20 (IO) 22 (IO) 
fiD (29) 6Y (34) Y2 (431 
0 0 U 
Q 0 U 
IY8 (Yl) IYI (Y.5) lY8 (93) 
2 
3 
5 
2 
3 
6 
7 
21 
52 
45 
95 + Y.7 
I32 * IY.8 
IIY -+ 20.0 
2 
4 
7 
6 
18 
49 
46 
IO 
25 
58 
4s 
74 z IO. I 
I30 + 17.X 
117 f IS.6 
74 ?: 10.3 0.77 
l3tJ I? 17.3 0.55 
II7 2 18.6 0.56 
-_I___ ---_11__- _I_ 
AECG = ambulatory ekctrocardi~~gram. 
_- -.. -_ 
among patients with angina (during one of the qualifying visit 
tests or in the 6 weeks before these tests) was similar in each 
treatment s rategy to the results for all patients (angina- 
guided strategy 35%. ischemia-guided strategy 3%. revas- 
Ftgure 3. Percent of Patients ischemia free on week 12 visit ambu- 
latory electrocardiogram for each treatment strategy. 
Guided Guided 
Strategy Strategy 
Strategy 
0.18 
0.03 
0.04 
75 (39) 78 (41) 105 (55) 
38 (20) 42 (221 2s (13) 
14 (7) I6 (9) 14 (7) 
II (6) 14 (7) 9 (51 
6 13) 6 (31 3 (2) 
30 (16) 21 (II) 27 (14) 
19 (IO) 12 (61 9 (S) 0.09 
II 13 20 
170 (83) 191 (XS) I75 (83) 
0 
I 
3 
0 
I 
2 
0 
0 
2 
0 
2 
I7 
44 
0 
I 
17 
44 
Q 
Q 
I5 
44 
0.11 
0.17 
II4 II2 I17 
71 + 10.7 67 + 8.9 93 f 11.9 .=I 0.001 
IIY + 17.6 II2 ? 17.3 123 5 19.0 < 0.001 
109 = 15.3 IO2 2 18.3 114 c 18.6 < 0.001 
(n = 104) (n = 101,’ (a = 82) 
cularization strategy 58%). Results for patients without 
angina were based on a smaller number of patients and 
showed no digerences among the treatment strategies 
(angina-guided strategy 48%, ischemia-guided strategy 49%, 
revascularization strategy 48%). The test of interaction 
between the presence or absence of angina nd treatment 
strategy yielded p = 0.09. The mean number of episodes at 
the qualifying visit was 5.2 for symptomatic patients and 3.9 
for asymptomatic patients. 
Analysis of change: qualifying visit to week 12. The 
number of ischemic episodes (adjusted for number of epi- 
sodes per 48 h at he qualifying visit) was significantly lower 
with the revascularization strategy compared with the 
angina-guided strategy (p < 0.001). The ischemia-guided 
strategy was not significantly different from the revascular- 
ication strategy (p = 0.19) or the angina-gc;ided strategy (p= 
0.04). The number of episodes atthe qualifying visit had a
modest effect on treatment differences (p = 0.03j. Similar 
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4 2.0 3 1.5 2 0.9 
10 4.9 6 3.0 5 2.4 
14 6.9 8 4.0 4 3.3 
A 15 1.4 ti 4.0 9 4.2 
-_ l-l_ll - - . . ..__ _ .-.pp ._ _.__ ~ 
*bJdkIlhJC CVCll Tat& CiIlKttCd method. CA G = cvtvnary artery bypass surgery; M1 = 
myocardial infarction confirmed by the vrhidity Classification Committee; PfCA = percutaneous 
I~~~S~U~~~U~ CWOtllWy Nl~iO~lilSty~ RS = patienls. 
the treadmill test. 
ST segment depression compared with 85% in the angina- 
guided or ischem~a~~~ided strategy and in 55% of 
assigned to the revasc~~ar~~at~~~ strategy. All three treat- 
ment strategies reduc 
and duration of ische 
rnonit~~~~g at the wee 
visit. Revascularizati 
strategy in reducing i 
T&le 5. Patients Randomized to Medical Regimens Without kchemia on Week 12 Visit 
Ambulatory Electrocardiogram 
Angina-Guided Ischemia- Both Medical 
Strategy: Guided Strategy: Strategies: 
No. of Pts (%I No. of Pts (%) p Value No. of Pts (%) 
A/N regimen n=64 n = 58 n = 122 
No ischemic episodes 26 (43) 28 (52) 0.32 54 (47) 
Data not available 3 4 I 
D!I regimen n = 57 n=6Q n= ?l7 
No ischemic episodes 19 (35) 17 (30) 0.64 36 (32) 
Data not available 2 4 6 
p value 0.37 O.G2 G.03 
Both regimens n = 121 n= II8 
No ischemic episodes 45 (39) 45 (41) 0.75 
Data not available 5 8 
-- -.--. - _.__---- ._.- 
Abbreviations as in Table 2. 
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Wii scribed for only 35% of patients assi 
Cd tion. 
e treadmill test results were concordant with those of 
ambulatory EC% monitoring. All three treatment st 
improved exercise tolerance and reduced exercise- 
angina and ECG evidence of ischemia. Bevascularization 
was the best strategy, increasing total exercise time and 
decreasing the percent of patients with exercise-induced 
angina nd ST segment depression. The two medical strate- 
gies were similar. 
The rates of death and myocardial infarction by 12 weeks 
were low, as expected, and were similar in all three treat- 
s. However, nonprotocol r~vascula~~atio~ (cor- 
ty and bypass urgery) was perfo 
ned to the an~n~.guid 
o either the ischemia-guided or the 
I three t~atment 
ided st~tegy was associated with more total events 
5. Cumulative petcent ofpatients with angina on treadmill 
test by time to onset for each treatment strategy at qualifying visit 
week 12 visit. Number of patients tested and symbols as in 
Fiire 4. 
Patients who unde~e 
most ischemia that can be medically suppressed may 
suppressed at low doses, and further suppression may re- 
antially higher doses or different drug combina- 
ether it is necessary to suppress all ischemic 
episodes tofavorably alter prognosis not known and needs 
to be tested. 
ime tiers to i-e- 
therapy. Because more than two-thirds of 
ned to medical therapy did not receive the 
second rug in the intended combination therapy, most of 
the relief of ischemia observed in this tudy can be ascribe 
to the first drug prescribed (i.e., atenolol in the atenolol plus 
nifedipine r gimen and diltiazem in the diltiazem plus isos- 
orbide dinitrate regimen. Suppression of ischemia on the 
ambulatory ECG was somewhat greater with the ateao~o~ 
plus nifedipine than the diltiazem plus isosorbide dinitrate 
drug regimen. Ambulatory ischemia was suppressed in 43% 
and 52% of patients assigned tothe atenolol plus nifedipine 
regimen versus only 35% and 30% of those assigned tothe 
JACC VQI. 24. NJ. I 
my 1994: I I-20 
uired for a larger c~~r~~ca~ trial. 
investigators found that 
asymptomatic is hemia occ 
atory ECG evidence of 
a~pro~~mate~y on  half of 
relatively severe coronary r-
ost were men ~60 years old; 70% had angina; -40% bad a 
evious myocardial infarction; and 15% to 40% bad one or 
more additional risk factors for adverse outcomes, uch as 
diabetes meltitus, current king or hypertension. Compli- 
ance with the complex A study treatmen: protocol was 
high; 90% of patients inthe medical strategies completed all 
scheduled visits. 
As seen in other major studies (e.g., the Coronary Artery 
Surgery Study [CASS]) inwhich revasc~larizati~~ is one of 
the therapeutic strategies, atients assigned to
undergo revascularization did not have the procedure (24). 
In the remainder, evascularization was performed in a 
timely manner, with good clinical outcome and consistent 
with current clinical practice. 
Very few patients assigned to one of the two regimens 
had to cross over to a drug of the other egimen, and both 
drug regimens were very well tolerated. The study also 
teal treatrrient strate should be started 0 
results are also E 
the treatment of asymp- 
owever, the apparent cost 
verse events. 
holism, responsible for 
seizures and multifocal abnormalities documented on electroen- 
cephalography. The patient was discharged after 6 weeks with no 
apparent neurologic impairment. A second patient underwent reop- 
eration for bleeding that occurred shortly after transfer to the 
intensive care unit. This patient was discharged in satisfactory 
condition I week after surgery. A third patient had reoperation 
hemorrhage with tamponade immediately 
the operating room. This patient later had 
infected groin incisions and congestive heart failure but MS dis- 
charged in stable condition 5 weeks after surgery. 
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